Browse studies

Find your next paid study

27,293 recruiting studies available now

A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel-Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD9550 and AZD6234

The purpose of this study is to examine the safety and tolerability of AZD6234 and AZD9550 in participants with hepatic impairment and participants with normal…

Hepatic Impairment

Estimated

~$500 – $11,250

Actual pay is set by the research site.

AstraZenecaNCT07546760

Phase 2

A Phase 2 Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Treatment-Experienced Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSC…

Non Small Cell Lung CancerAdvanced Non Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer+1 more

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Regeneron PharmaceuticalsNCT07154290

Phase 1

A Phase 1b Study of Gilteritinib in Participants With Locally Advanced or Metastatic NSCLC With ALK Rearrangement After Prior Treatment With an ALK Inhibitor

Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in…

Non-small Cell Lung Cancer (NSCLC)Anaplastic Lymphoma Kinase (ALK) Positive

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Astellas Pharma Global Development, Inc.NCT07140016

Evaluation of the PACE/PACENET BHL Clinical Program

The SUpporting Seniors Receiving Treatment And INtervention (SUSTAIN) program is a telephone-based clinical service designed to help identify and manage behavi…

DepressionAnxietyPain, Chronic

Estimated

~$10 – $750

Actual pay is set by the research site.

University of PennsylvaniaNCT02463266

Post-market Evaluation of Incidence Rate of Anaphylaxis and Hypersensitivity Reactions Associated With LUMISIGHT Administration

This study is a prospective, multi-center, observational post-market safety study evaluating the incidence of anaphylaxis and hypersensitivity reactions associ…

Hypersensitivity Reactions

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Lumicell, Inc.NCT07572162

A Prospective Natural History Study of Lymphatic Anomalies

Background: The lymphatic system is a network of vessels that carry a clear fluid called lymph through the body. Problems in the lymphatic system can cause pa…

Lymphatic DiseasesLymphatic Abnormalities

Estimated

~$10 – $675

Actual pay is set by the research site.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NCT05731141

Phase 2

Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL) - (Optimizing Acute Stress Reaction Interventions With TNX-102 SL - OASIS)

This study will examine the safety and efficacy of TNX-102 SL to reduce ASR symptoms and behavioral changes among patients presenting to the emergency departme…

Acute Stress ReactionAcute Stress DisorderNeurocognitive Function+1 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

University of North Carolina, Chapel HillNCT06636786

Phase 1

RALLY-MF: A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

This phase 1b/2a open-label study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of DISC-0974 as well as cat…

Myelofibrosis; AnemiaAnemiaMyelofibrosis+4 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Disc Medicine, IncNCT05320198

Phase 3

A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1 Receptor Agonists to Maridebart Cafraglutide in Adult Participants With Obesity or Overweight

Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.

Obesity or Overweight

Estimated

~$50 – $2,250

Actual pay is set by the research site.

AmgenNCT07575399

Observational

Comparative Effect of Training Methods to Reduce Forefoot Loading in Carbon Fiber Custom Dynamic Orthoses

Carbon fiber custom dynamic orthoses (CDOs) include a full-length footplate, a stiff posterior spring, and a cuff that wraps around the leg below the knee. CDO…

Healthy

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Jason WilkenNCT07889765

Long-Term CLinical Evaluation of Aspiration ThRombectomy Using the Symphony or ProdIgy Thrombectomy System - CLEAR-IT

The study is designed to evaluate the short-term and long-term clinical performance and safety of the Symphony and Prodigy thrombectomy systems used in endovas…

Arterial ThromboembolismVenous ThromboembolismPulmonary Embolism

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Imperative Care, Inc.NCT07350499

Phase 1

A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin in Patients With Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas

This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sar…

Metastatic Dedifferentiated LiposarcomaMetastatic LeiomyosarcomaMetastatic Myxofibrosarcoma+9 more

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Cancer Institute (NCI)